COVID-19 UPDATES >VISIT JANSSEN GLOBAL
Collaborating in more than 150 countries.By clicking on a link below, you may enter a different part of this website, or a website outside of Janssen.com. These sections or websites are governed by their own Legal and Privacy Policies.
Asia Pacific (Regional)
English | Fran?ais | Nederlands
Deutsch | Fran?ais
Central America and the Caribbean
Spanish | English
English | Fran?ais
Welcome to Xian Janssen
Johnson & Johnson Outlines Strategy to Deliver Above-Market Growth at 2019 Pharmaceutical Business Review
Highlights progress and commitment to deliver breakthrough medicines to meet the needs of patients around the world
Plans to maximize potential of...
[Media Report] Serving In the Name of Progress
(Joaquin Duato, executive vice-president and worldwide chairman of pharmaceuticals at Johnson & Johnson)
A senior executive at...
China Food and Drug Administration approves IMBRUVICA? (ibrutinib) for the treatment of two forms of blood cancer with high unmet treatment needs
[Beijing], [30 August, 2017] – Xian Janssen Pharmaceutical Ltd. announced today that the China Food and Drug Administration (CFDA) has approved IMBRUVIC...
Follow us on WeChat